Dr Graham E Kelly, BSc(Vet), BVSc, PhD, Chairman
Dr Kelly was appointed Chairman of MEI in April 2002. Dr Kelly founded Novogen Limited and has spent nearly 30 years in medical research involving drug development, immunology, surgery and cancer. Dr Kelly was senior research fellow in experimental surgery in the Faculty of Medicine at the University of Sydney. He developed the beta 1, 3-glucan and isoflavone intellectual property now owned by the Novogen Group. Dr Kelly was Executive Chairman of Novogen between 1997 and 2000 and will continue to act as project leader for phenoxodiol.
Christopher Naughton, BEc, LLB, President and CEO
Mr Naughton is the President and CEO of MEI. He is also the Managing Director of Novogen Limited. Mr Naughton has degrees in Economics from the Australian National University and in Law from the University of New South Wales. He has completed the Program for Management Development at the Harvard Business School and is admitted to practise as an attorney in New South Wales. After working in merchant banking he has spent the last 15 years in the pharmaceutical industry including appointments as Director of Wellcome Australia Limited and in world wide business development with the Wellcome Foundation Limited in the UK
Phillip A Johnston, Dip Eng (Production), Non-Executive Director
Mr Johnston has had extensive experience in the pharmaceutical industry. He has been a Non-Executive Director of Novogen Limited since January 1997 and Chairman of Novogen since January 2001.Mr Johnston spent 9 years as an Executive Director of Wellcome Australia Limited. He was previously a Director of two subsidiary companies of GlaxoWellcome. His responsibilities have encompassed production, distribution, quality assurance and consumer product development and he has been directly involved in the establishment of strategic alliances and joint ventures. Mr Johnston has completed a number of executive development programs including programs at the University of New South Wales and the London Business School.
Professor David Morritz de Kretser, AO FAA, MBBS, MD, FRACP, Non-Executive Director
Professor de Kretser is currently Executive Chair at the Monash Institute of Health and Associate Dean for Biotechnology Development at Monash University as well as being the Director of the Australian Centre for Excellence in Male Reproductive Health. He was the Founding Director of the Monash Institute of Reproduction and Development and remains as the Director of the Centre for Molecular Reproduction and Endocrinology within the Institute. Professor de Kretser has been active in medicine and research for over 30 years, taking on roles including Professor of the Department of Anatomy, Monash University. He has served on numerous international and national committees dealing with research and has experience on a number of professional editorial boards. He has published over 400 research papers and has been invited to speak at numerous national and international conferences and symposiums on topics such as fertility, andrology and endocrinology. Professor de Kretser's research has led to a number of patents in Australia and overseas. He is an Officer of the Order of Australia, a Fellow of the Australian Academy of Science and a Fellow of the Australian Academy of Technological Sciences and Engineering.
Professor Paul John Nestel, AO MD, FTSE, FRACP, Non-Executive Director
Professor Nestel is currently a Non-Executive Director of Novogen and Senior Principal Research Fellow and Head of the Cardiovascular Nutrition Laboratory at the Baker Medical Research Institute, Victoria. Professor Nestel is also a Consultant Physician at the Alfred Hospital, Melbourne; and Chair, University of Wollongong Advisory Board, Centre of Excellence. He was formerly Clinical Professor of Medicine, The Flinders University of South Australia. Professor Nestel is an Officer of the Order Of Australia.
Stephen Breckenridge, M Tax, FCA, FTIA, Non-Executive Director
Mr Breckenridge has had over 25 years experience in public practice as a Chartered Accountant in Australia and is currently Managing Director of Breckenridge Consulting Pty Ltd which provides independent tax and management advice to multi-nationals and SME's. Until 2001 Mr Breckenridge was a tax partner for 24 years with KPMG in Sydney where he provided corporate tax advice to a wide cross section of business in Australia and overseas with particular emphasis in more latter years on international transfer pricing. Mr Breckenridge has also been involved in the pharmaceutical and chemical industries over a long period including serving on several industry association committees and leading industry focus groups within KPMG. Mr Breckenridge holds a Master of Tax degree from the University of Sydney and is a Fellow of the Institute of Chartered Accountants and the Taxation Institute of Australia.
updated 2nd March, 2004
| © Copyright 1996-2015 irasia.com Ltd. All rights reserved. |
|
DISCLAIMER: irasia.com Ltd makes no guarantee as to the accuracy or completeness of any
information provided on this website. Under no circumstances shall irasia.com Ltd be liable
for damages resulting from the use of the information provided on this website.
TRADEMARK & COPYRIGHT: All intellectual property rights subsisting in the contents of this website belong to irasia.com Ltd or have been lawfully licensed to irasia.com Ltd for use on this website. All rights under applicable laws are hereby reserved. Reproduction of this website in whole or in part without the express written permission of irasia.com Ltd is strictly prohibited. TERMS OF USE: Please read the Terms of Use governing the use of our website. |